MD&AThat was a detailed review that they published today. Their strategy is sound and as supply chains diminish, this plan has to begin to resonate to the competition in the contrast drug market. The points raised by the competition in this document on supply chain are important, Voyageurs timing is excellent.
The iodine project is going to add massive value.
The fullerene is going to add massive value.
I am curious of the lack of financing news, only thing that makes sense is something is brewing behind the scenes. This project is too important for Canada and the USA. They are the only drug company in North America that is creating their own strategic minerals. China and EU are going to be toast for supply very soon.